EGFR and cancer: While the normal EGFR signaling cascade is initiated by ligand-dependent dimerization and subsequent trans-phosphorylation of tyrosine residues within the cytoplasmic tail of the receptor, constitutively active mutant EGFRs associated with human cancer are thought to engage downstream signaling pathways in a constitutive fashion.